ID: MRFR/HC/5956-HCR | 110 Pages | Published By Rahul Gotadki on March 2023
Leukemia therapeutics market is expected to grow significantly over the forecast period. It is anticipated that the market held value of USD 26,881.88 million in 2030 and is projected to grow at a CAGR of 7.50% over the forecast period.
Leukemia Therapeutics Market Overview
The market will hold a CAGR of 7.50% and a value of USD 26 881.88 million by 2030. The market will have high growth in the coming years if the market grows at the same pace. Cancer is a disease of genes caused by the uncontrolled growth of the cells in the body. The affected cells can further spread into another body site from that part through the blood and lymph system. It is known as blood cancer which commonly can happen to adults or children. Several types of leukemia are there, and leukemia therapeutics are used to treat them. The factors that improve the market are the rise of the older population, lifestyle changes, and others are some of the major causes of the market growth. However, the constraint that also hampers the growth pace is the high cost needed to develop new therapeutics. It makes an individual weak and loses the ability to fight any infection. The awareness among people regarding cancer disease and the sudden availability of detection and diagnosis will create more opportunities for the market. Common symptoms of this disease are fatigue, weight loss, frequent infections, easy bleeding or bruising, and some others.
Leukemia Therapeutics Market Segmentation
The global leukemia therapeutics market has been segmented into type, applications, and region.
Based on type, market is segmented into chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant. The chemotherapy segment is expected to account for the largest share segment of the market in 2017. Chemotherapy segment further sub segmented into alkylating agents, antimetabolites, antitumor antibiotics, and others.
Based on applications, market is segmented into acute lymphocytic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, and others.
The market segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The market in the Americas further segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The leukemia therapeutics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The market in the Middle East & Africa segmented into the Middle East and Africa.
Regional Market Summary
Geographically, the Americas is anticipated to dominate the global leukemia therapeutics market owing to a well-established player, innovative therapies to drive the market for leukemia, increase prevalence of leukemia, and increasing older population.
Europe is expected to hold the second largest position in the global market. The market growth in this region is attributed to increase prevalence of leukemia.
The market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region.
The Middle East & Africa has the least share of the leukemia therapeutics market.
Market of Leukemia Therapeutics, by Treatment Type
Market of Leukemia Therapeutics, by Application
Market of Leukemia Therapeutics, by Region
Market of Leukemia Therapeutics, by Key Players
BeiGene is a worldwide science-driven biotechnology company that focuses on developing innovative and affordable medicines to improve treatment. It outcomes and access for patients worldwide. The company recently announced that the China National Medical Products Administration (NMPA) had granted conditional approval of BLINCYTO® for injection for the treatment of pediatric patients with relapsed or refractory (R/R) CD19-positive B-cell precursor acute lymphoblastic leukemia. The NMPA gave conditional approval for adult patients in this indication in December 2020.
Curis, Inc., a biotechnology company, focuses on developing innovative therapeutics to treat cancer. Intended Audience
|Market Size||2030: USD 26,881.88 Million|
|CAGR||7.50% (2020- 20230)|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||By Type, Application, Regions|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Eisai Co., Ltd (Japan), Novartis AG (Switzerland), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche AG (Switzerland), Sanofi S.A. (France), Teva Pharmaceutical Industries Ltd (Israel), Amgen Inc (US), and Takeda Pharmaceutical Company Ltd (Japan).|
|Key Market Opportunities||Joint ventures, strategic alliances, mergers and acquisitions and new product developments|
|Key Market Drivers||
The market is projected to grow at a 7.50% CAGR between 2020-2030
The Americas is expected to dominate the market.
The acute lymphocytic leukemia segment will dominate the market.
Increasing prevalence of leukemia, increasing older population, and availability of innovative therapies are boosting market growth.
High cost may restrict the growth of the market.